Please assess the completion status of the following clinical trial:

Trial Title: The Role of Intra-articular Injection of PRP Versus Corticosteriods in Treatment of Lumbar Facet Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Continuous or intermittent gradually progressive back pain for more than 3 months not significantly improving on medical treatment and/or physical modalities.~  * Patients age between 20 and 40 years.~ * Local / paraspinal pain or tenderness with or without radiation to buttock , groin or thigh.~ * Increase of pain on extension , rotation or lateral bending .~ * MRI detected synovitis of the facet joint as defined and graded by Czervionke and Fenton, 2008.~Exclusion Criteria:~* • Acute low back trauma, fractures, malignancies and inflammatory diseases.~  * Pain score of \< 4 at rest on visual analog scale.~ * Radicular neurologic complaints.~ * X-ray findings of long standing facet joint disease as; marked joint space narrowing, subchondral sclerosis or bone deformity/ sponylolithesis.~ * Evident disc herniation by MRI.~ * Prior surgery on the spine.~ * Prior interventional treatment on lumbar facet joints~ * Known hypersenstivity to local anesthesia, corticosteroid, contrast medium or blood derivatives.~ * Local or systemic infection or spinal infection.~ * Uncorrectable coagulopathy~ * Diabetes Mellitus~ * Pregnancy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Group (I) Platelet Rich Plasma (Type: ACTIVE_COMPARATOR): The participants are randomly assigned for intra-articular injection with autologous platelet rich plasma . The treated segments are determined by clinical signs and MRI detected facet joint synovitis .
- Group (II) Corticosteroids (Type: ACTIVE_COMPARATOR): The participants are randomly assigned for intra-articular injection with corticosteroids(a mixture of 0.5% lidocaine and 5mg/ml of betamethasone) . The treated segments will be determined by clinical signs and MRI detected facet joint synovitis .

Based on this trial design, predict the completion outcome and termination type (if applicable).